Neoplastic transformation is a consequence of maladaptive alterations in the cellular processes normally involved in cell growth, proliferation, differentiation, and survival. Despite the relative infrequent nature of skeletal neoplasms, current understanding of the pathobiology underlying these conditions is becoming increasingly characterized. This article highlights some of the established molecular abnormalities identified in various benign and malignant skeletal neoplasms and how they pertain to tumor biology, diagnosis, and prognosis. Most of the commonly accepted cellular aberrancies in skeletal neoplasms pertain to mutations, copy number changes, and/or chromosomal rearrangements. However, it is becoming increasingly understood that the complexity of tumorigenic pathways necessary for neoplastic growth are manipulated by numerous overlapping alterations in the genetic code and are further influenced by higher-order molecular programs, such as pretranscriptional and posttranscriptional regulation and chromatin reorganization. Over time, identification and quantification of these increasingly recognized neoplastic processes will gradually translate into valuable clinical applications, enhancing the current diagnostic and prognostic capabilities. (J Natl Compr Canc Netw 
Despite the increasing complexity of cellular pathways involved in cell growth, proliferation, and differentiation, the central tenet of oncogenic transformation involves the collective dysregulation of 7 key regulatory cell pathways: self-sufficiency in growth signals, insensitivity to antigrowth signals, evasion of apoptosis, limitless replicative potential, angiogenesis, metastasis and tissue invasion, and immune evasion.
1,2 Subtle differences in how these essential pathways are disrupted dictates the various biological attributes of different benign and malignant neoplasms, and greatly influences clinical variation among different patients with an identical diagnosis.
Perhaps because of limits in current understanding, neoplasia is considered to be a genetic disease process. Neoplastic cells will ultimately display different tissue traits, speed of growth, or responsiveness to outside signals because they express different levels of certain proteins or express uniquely altered proteins that gain nonnative functions. These proteins all derive from genes, leading to an understanding of neoplasia and oncogenic transformation primarily through genes.
Much investigational effort in the past decade has elucidated a variety of mechanisms to impact gene expression. Certainly some neoplastic genetic aberrations derive from deleterious alterations in the genetic code itself, such as gene mutations, amplifications, deletions, or higher-order events that alter chromosomes, but many more are likely dysregulated through nongenetic or epigenetic mechanisms, such as micro-RNAs or chromatin remodeling. Historically, as much was learned about the genes lost specifically in cancer cells by studying the germline genetics of heritable cancer predisposition syndromes 20 years ago, most of the nongenetic molecular mechanisms at work in neoplasia is understood by translating each mechanism into the more tractable language of which genes or pathways each upregulates or downregulates.
Currently, none of these not-strictly-genetic molecular mechanisms that are likely at work in neoplasia have even approached clinical importance in the field of bone tumors; although they probably will in the future, this review focuses on genes instead. Even the application of genetic knowledge to bone tumors strays deeply into the research realm and away from clinical standards and practices. For each specific genetic association discussed, it will be made clear which have clinical implications currently or in the foreseeable future. Study of the other lesserunderstood genetic associations focuses on the hope that understanding the genetic mechanisms of disease will highlight improved targets for therapy or diagnostic testing.
Benign Bone Neoplasms Osteochondromas
Osteochondromas are one of the most common benign skeletal neoplasms, characterized by a cartilagecapped bony outgrowth, which is contiguous with the underlying medullary canal. The cell of origin is a proliferating chondrocyte derived from the growing physis. 3 The hallmark genetic abnormality in these cartilage growths is biallelic inactivation of the EXT1 or EXT2 gene in some portion of the chondrocytes. These gene inactivations are either acquired sporadically or through loss of heterozygosity after inheriting one inactive allele. The latter, hereditary form is called multiple osteochondromas (MO) or multiple hereditary exostosis (MHE). Both EXT gene products are fundamentally involved in heparan sulfate (HS) synthesis, and HS deficiency in physeal chondrocytes is thought to promote proliferation and loss of polarity. 4 In nearly 80% of sporadic osteochondromas, biallelic loss of EXT1 is observed in the cartilaginous cap. 5 MHE is an autosomal dominant condition, characterized by a heterozygous mutation in either EXT1 or EXT2 in 65% and 35% of cases, respectively. 6 The risk of malignant transformation to secondary peripheral chondrosarcoma is rare: less than 1% of solitary lesions and 1% to 5% in patients with MHE. 12 IDH1 mutations are also observed in other benign and malignant cartilaginous neoplasms, such as periosteal chondroma and central chondrosarcoma, while absent from others, such as synovial chondromatosis, chondroblastoma, chondromyxoid fibroma, and clear cell chondrosarcoma. 10, 11 The risk of malignant transformation in solitary enchondromas is rare, whereas malignant degeneration into secondary central chondrosarcomas occurs in 25% to 50% and greater than 50% of patients with Ollier disease and Maffucci syndrome, respectively. 13, 14 Lesions involving the pelvic bones in these patients are particularly high risk.
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Fibrous Dysplasia
Fibrous dysplasia is a benign monostotic or polyostotic fibro-osseous metaplasia involving the medullary bone cavity and cortex. Lesions often develop during adolescence or early adulthood, but can remain undetected for years. Similar to enchondromatosis, fibrous dysplasia results from a postzygotic mutation, in this case an activating mutation in the GNAS gene, which encodes the α-subunit of the stimulatory protein, GS-α. 15 Replacement of Arg201 with a Cys or His residue results in constitutive activation of GS-α, which in turn constitutively activates adenylyl cyclase, resulting in the accumulation of cyclic adenosine monophosphate and stimulation of various downstream cellular processes. 16 It has been demonstrated that GNAS mutations in marrow stromal cells impair differentiation potential into adipocyte lineages and promotes osteoclastogenic signaling, mediated partly by receptor activator of nuclear factor-κB ligand and interleukin 6. 15 These alterations impair the normal cellular and mechani-cal architecture of the local marrow cavity, giving rise to the classic skeletal lesions observed in fibrous dysplasia. Generalized osteomalacia can also be associated with fibrous dysplasia attributable to elevated serum levels of fibroblast growth factor-23 (FGF-23). Posttranslational modification of inactive FGF-23 (iFGF-23) by fibrous dysplasia cells is thought to result in increased circulating levels of active FGF-23 (cFGF-23), which acts on the kidney to promote a net phosphate loss. 17 It has been suggested that quantification of serum FGF-23 levels can provide an indirect measure of disease burden in fibrous dysplasia, although this is not yet used widely.
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Aneurysmal Bone Cyst
Aneurysmal bone cysts (ABCs) are locally aggressive, benign, expansile bone lesions characterized by multiloculated blood-filled cystic cavities. ABCs can present as primary lesions or secondary lesions within other benign and malignant neoplasms, such as giant cell tumor of bone, osteoblastoma, fibrous dysplasia, chondrosarcoma, and osteosarcoma. Although decidedly lacking any metastatic potential, ABCs are highly destructive, promote mechanical insufficiency in the host bone, and frequently recur after excision. Approximately 70% to 80% of primary ABCs harbor a somatic translocation involving rearrangement of the ubiquitin specific peptidase 6 (USP6) gene on chromosome 17, most commonly to the cadherin 11 gene (CDH11) on chromosome 16 (t16:17) . 19 Other fusion partners include TRAP150, ZNF9, OMD, and COL1A1, although they account for less than 30% of translocation-positive ABCs. Rather than generating fusion protein products, these translocations bring the USP6 gene expression under the control of the promoters of the more highly expressed partner loci. These rearrangements occur in a low-prevalence spindle cell population within the ABC. The increased transcriptional level of USP6 is thought to facilitate tumorigenesis via nuclear factor-κB (NF-κB) induction of matrix metalloproteinase expression and recruitment of many reactive cells that constitute most of the tumor tissue. 20 The diagnostic utility of detecting USP6 rearrangements is questionable given the absence of these abnormalities in 30% of primary lesions and all secondary lesions, and lack of any treatment or prognostic implication of molecular testing.
Malignant Bone Tumors Conventional Osteosarcoma
Conventional osteosarcomas are high-grade lesions characterized by a plethora of complex numerical and structural chromosomal abnormalities. This high degree of chromosomal instability in osteosarcoma predisposes to significant intra-and intertumoral heterogeneity. 21 Regardless, high-resolution microarray and in situ hybridization studies have identified consistent genomic regions of copy number amplifications and deletions in conventional osteosarcoma.
Deletions or copy number losses of the retinoblastoma gene RB1 (13q14), TP53 (17p13), CDKN2A (9p21), and LSAMP (3q13) are common observations in conventional osteosarcoma. Osteosarcomas are the second most common malignancy in patients with hereditary retinoblastoma, attributable to mutations within or epigenetic inactivation of the RB1 locus. A total of 60% of retinoblastoma cases are the result of sporadic mutations/inactivation, whereas 40% are an inherited autosomal dominant germline mutation with 100% penetrance. 22 The RB protein is one of the master regulators of cell cycle progression, involved in G1 checkpoint control, regulation of apoptosis, maintenance of senescence, chromosome stability, and chromatin organization. 22 The RB protein also functions as a transcriptional coactivator of osteoblast differentiation, which may explain why inactivation of the RB1 gene predisposes to osteosarcomagenesis. 23 Roughly 35% of sporadic osteosarcomas are associated with direct inactivation of the RB1 locus (DNA mutations, loss of heterozygosity, and deletion), although RB inactivation does not seem to correlate with prognosis. 24 Mutations or losses at the TP53 locus are also common in sporadic osteosarcomas, present in 40% of cases. Similar to the RB protein, TP53 is an essential tumor suppressor protein that functions as a transcriptional activator for a variety of vital cellular processes, such as initiation of DNA repair, cell cycle arrest, senescence, and apoptosis. 25 In 10% of cases, amplifications of the MDM2 locus (12q15) are observed, which functions as a TP53 antagonist. In parosteal osteosarcomas (low grade, surface variant), MDM2 amplifications are observed in 80% to 90% of cases, often associated with a supernumerary ring chromosome. 26 Again, similar to RB inactivation, TP53 loss does not prognosticate histologic response to chemotherapy or overall survival. 27 The CDKN2A locus encodes for 2 important tumor suppressor genes: INK4A (also called p16) and ARF (also called p14). Both are translated from the same transcript, the second from an alternate reading frame (the source of its name). INK4A loss essentially silences the RB1 cell cycle checkpoint, and ARF loss concomitantly silences the TP53 cell cycle checkpoint. CDKN2A is deleted in 15% of conventional osteosarcomas and has been associated with inferior clinical outcomes. 28 LSAMP is a membrane-associated protein originally associated with development of the central nervous system, but recent reports have suggested that it also functions as a tumor suppressor in osteosarcoma. 29 LSAMP loss also seems to be associated with advanced disease and poor survival. 29, 30 Alternatively, the 2 most common amplified genomic regions observed in conventional osteosarcoma house the RUNX2 gene and the MYC oncogene. Both of these targets are amplified in 40% to 50% of cases. RUNX2 expression is associated with osteoblast differentiation, and overexpression in osteosarcomas is associated with an inferior histologic response to chemotherapy.
31
Chondrosarcomas
Primary central chondrosarcoma is classified primarily based on histologic grade. Presently, histologic grade also remains the single most important prognostic variable. IDH1 and IDH2 mutations are observed in 50% to 60% of primary central chondrosarcoma cases, in contrast to a mutation frequency of 50% and 90% in solitary enchondromas and multiple enchondromas associated with Ollier disease and Maffucci syndrome, respectively. IDH1 and IDH2 mutations are not observed in osteosarcomas, and therefore the detection of IDH1 mutations has been suggested as a means to differentiate chondroblastic osteosarcomas from chondrosarcomas in ambiguous cases. 10, 11 IDH1 and IDH2 mutations are also observed in periosteal chondrosarcomas and secondary central chondrosarcomas, but not osteochondromas or secondary peripheral chondrosarcomas. 11 Interestingly, in secondary peripheral chondrosarcomas, homozygous EXT1 or EXT2 mutations are not common, despite their prevalence in osteochondromas. 32 These results suggest that malignant transformation of osteochondromas to form peripheral chondrosarcomas often occurs in the wild-type chondrocyte passenger cells in the mosaic cartilaginous cap.
Complex copy number alterations and polyploidization are associated with increasing histologic grades in chondrosarcomas. 33 Dysregulation of the RB1 pathway is present in more than 80% of highgrade lesions. 34 In dedifferentiated chondrosarcomas, which are associated with dismal 5-year survival, IDH1/IDH2 mutations are also common (50%), as are TP53 mutations and MYC amplifications. Many of these mutations and amplifications are shared between both differentiated and dedifferentiated components, suggesting a common cellular origin. 35, 36 
Ewing Sarcoma
Ewing sarcoma is a quintessential translocationassociated malignancy; virtually all tumors harbor a balanced chromosomal translocation fusing the EWSR1 gene on chromosome 22 with 1 of 5 members of the ETS family of transcription factors. The EWS/FLI fusion, t (11;22) , is most common, constituting 85% of cases, followed by EWS/ ERG (5%-10%). Fusions involving ETV1, ETV4, and FEV are infrequent, representing fewer than 5% of cases together. 37 Other Ewing-like sarcomas have been observed, characterized by EWS fusions to other non-ETS proteins, such as NFATc2, SMARCA5, PATZ1, and SP3. Ewing sarcomas are frequently recognized as a "small round blue cell" malignancy, characterized by monolayered, homogenous, undifferentiated malignant cells. Histologic preparations of Ewing sarcoma usually stain with immunohistochemistry against the membrane-associated protein CD99, although lymphoblastic leukemias, synovial sarcomas, and myeloid sarcomas may also stain for CD99, rendering the test anything but pathognomonic. 38, 39 Consequently, molecular studies directed at detecting EWSR1 rearrangements via reverse transcriptase PCR or fluorescence in situ hybridization with an EWSR1 break-apart probe are now used in concert with histologic evaluation to render a definitive diagnosis. These tests do not negate the need for appropriate clinical history and diagnostic imaging, because other musculoskeletal sarcomas harbor EWSR1 rearrangements, such as desmoplastic round cell tumor (EWS/WTI), extraskeletal myxoid chondrosarcoma (EWS/NRYA3), myxoid liposarcoma (EWS/DDIT3), and clear cell sarcoma (EWS/ATF1).
EWS/FLI and related EWS/ETS chimeras are potent oncogenic transcription factors, known to up-and downregulate numerous direct and indirect target genes important for oncogenesis. 40 One of these direct targets, NKX2.2, is a transcription factor responsible for a significant portion of the EWS/FLI-repressed transcriptional signature, 40 and positive immunostaining for this protein has been shown to differentiate Ewing sarcoma from other small round blue cell malignancies, with a sensitivity and specificity of 93% and 89%, respectively.
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TP53 mutations and CDKN2A deletions are infrequent in Ewing sarcoma (10%-15% of cases). Loss of either has been associated with inferior clinical outcomes, although this remains controversial. 42 The type of EWS/ETS fusion or the varied EWSR1 breakpoints are not considered prognostic. 43, 44 Like other malignant bone tumors, the clinical detection of metastatic disease is the most important prognostic indicator in Ewing sarcoma. Table 1 summarizes the identified molecular abnormalities associated with various benign and malignant bone neoplasms. Importantly, despite the increasing discovery of genetic mutations, copy number variations, and molecular dysregulation essential for tumorigenesis in skeletal neoplasms, most cases remain diagnosed through integrating clinical information with detailed radiographic studies and meticulous histologic evaluations. Except for Ewing sarcoma, most molecular diagnostic tests for malignant bone neoplasms are not pathognomonic of a specific tissue diagnosis. As each is also expensive and technically challenging, the use of most molecu- lar characterization of bone neoplasia is currently reserved for research purposes or the deciphering of ambiguous cases. Currently, histologic grade and detectable disseminated disease remain the most important prognostic variables for malignant bone sarcomas. However, the ongoing elucidation of key, measureable molecular pathways associated with important variations in tumor biology may soon provide the opportunity to more effectively stratify individual disease behaviors and select more efficacious, targeted therapies.
Conclusions
